🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,067 results for “Hospital” Clear

  1. Orelabrutinib

    The First People's Hospital of Lianyungang

    Primary Central Nervous System Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  2. Orelabrutinib

    The First People's Hospital of Lianyungang

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 2 small molecule active

    1 trial

  3. Orelabrutinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  4. Organoid-guided treatment

    The First People's Hospital of Lianyungang

    HER2-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  5. Osteosheet(r)

    Hospital Authority, Hong Kong

    Orbital Trauma

    phase 2 other completed

    1 trial

  6. Oxaliplatin, 5FU, leucovorin

    Hospital Authority, Hong Kong

    Biliary Cancer Metastatic

    phase 2 small molecule active

    1 trial

  7. PACLITAXEL AHCL 6 mg/ml, solution à diluer pour perfusion, Erbitux 5 mg/mL solution for infusion, CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion

    Ningbo Cancer Hospital

    Head and neck squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  8. PBSC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stem Cell Transplantation, Hematopoietic

    phase 2 mab active

    1 trial

  9. PBSC transplantation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Cirrhosis

    phase 2 other active

    1 trial

  10. PC-SOD

    The First People's Hospital of Lianyungang

    Myocardial Reperfusion Injury

    phase 2 small molecule active

    1 trial

  11. PCAR-019 (anti-CD19 CAR-T cells)

    The First People's Hospital of Lianyungang

    Acute Lymphocytic Leukemia

    phase 2 mab active

    1 trial

  12. PD -1/PD-L1 monoclonal antibody plus radiotherapy and liver transplantation

    The First People's Hospital of Lianyungang

    Locally Advanced Perihilar Cholangiocarcinoma

    phase 2 other active

    1 trial

  13. PD-1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Cancer Patients

    phase 2 small molecule active

    1 trial

  14. PD-1 antibody Sintilimab

    The First People's Hospital of Lianyungang

    Multiple Primary Lung Cancers

    phase 2 small molecule active

    1 trial

  15. PD-1 inhbitor+SHR0302

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. PD-1 inhibitor

    The First People's Hospital of Lianyungang

    Advanced NSCLC

    phase 2 small molecule active

    1 trial

  17. PD-1/CTLA-4 Dual Functional Antibody

    The First People's Hospital of Lianyungang

    Bile Duct Carcinoma

    phase 2 small molecule active

    1 trial

  18. PD-1inhibitor

    Shanghai Chest Hospital

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  19. PEG-somatropin

    The First People's Hospital of Lianyungang

    Dwarfism

    phase 2 small molecule active

    1 trial

  20. PEG-somatropin

    The First People's Hospital of Lianyungang

    Short Stature Children Born Small for Gestational Age (SGA)

    phase 2 mab active

    1 trial

  21. PEX168 or placebo

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type 2 Diabetes

    phase 2 small molecule completed

    1 trial

  22. PF-07248144, FULVESTRANT ZENTIVA 250 mg, solution injectable en seringue préremplie, PF-07248144

    Ningbo Cancer Hospital

    Adult patients with advanced hormone receptor positive (HR+), HER2- breast cancer after at least a first line of endocrine therapy combined with CDK4/6 inhibitor in the metastatic setting

    phase 2 small molecule active

    1 trial

  23. PG2

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Stroke

    phase 2 small molecule completed

    1 trial

  24. PI3K inhibitor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoma, T-Cell

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources